Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTS74QB)

• DTT Name: Inhibitor of apoptosis protein (hIAP)
• Synonyms: Baculoviral IAP repeat-containing protein
• Gene Name: XIAP
• DTT Type: Clinical trial target; [1]
• UniProt ID: XIAP_HUMAN ; BIRC2_HUMAN ; BIRC3_HUMAN ; BIRC1_HUMAN ; BIRC7_HUMAN ; BIRC5_HUMAN
• TTD ID: T61683
• Sequence:
  MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDT
  VRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENY
  LGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLT
  PRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSE
  SDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKC
  FHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTP
  SLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKD
  SMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDK
  CPMCYTVITFKQKIFMS
• Function: A class of key apoptosis regulators. Influences a multitude of other cellular processes, such as ubiquitin (Ub) dependent signaling events that regulate activation of nuclear factor B (NFB), which in turn drive the expression of genes important for inflammation, immunity, cell migration and cell survival. Modulates signaling events that promote the activation of cell motility kinases and metastasis11 and they regulate mitogenic kinase signaling, proliferation and mitosis.
• KEGG Pathway:
  Platinum drug resistance (hsa01524)
  NF-kappa B signaling pathway (hsa04064)
  Ubiquitin mediated proteolysis (hsa04120)
  Apoptosis (hsa04210)
  Apoptosis - multiple species (hsa04215)
  Necroptosis (hsa04217)
  Focal adhesion (hsa04510)
  NOD-like receptor signaling pathway (hsa04621)
  Toxoplasmosis (hsa05145)
  Human T-cell leukemia virus 1 infection (hsa05166)
  Pathways in cancer (hsa05200)
  Chemical carcinogenesis - receptor activation (hsa05207)
  Small cell lung cancer (hsa05222)
• Reactome Pathway:
  SMAC (DIABLO) binds to IAPs (R-HSA-111463)
  SMAC(DIABLO)-mediated dissociation of IAP (R-HSA-111464)
  SMAC, XIAP-regulated apoptotic response (R-HSA-111469)
  Deactivation of the beta-catenin transactivating complex (R-HSA-3769402)
  RIPK1-mediated regulated necrosis (R-HSA-5213460)
  Regulation of TNFR1 signaling (R-HSA-5357905)
  TNFR1-induced NFkappaB signaling pathway (R-HSA-5357956)
  Regulation of necroptotic cell death (R-HSA-5675482)
  Regulation of PTEN localization (R-HSA-8948747)
  Regulation of PTEN stability and activity (R-HSA-8948751)
  Regulation of the apoptosome activity (R-HSA-9627069)
  Activation of caspases through apoptosome-mediated cleavage (R-HSA-111459)

Molecular Interaction Atlas (MIA) of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT-406	DMVJW0S	Squamous head and neck cell carcinom	2D60.0	Phase 3	[2]
LCL161	DMTM4QA	Multiple myeloma	2A83	Phase 2	[1]
APG-1387	DMLEKUY	Haematological malignancy	2B33.Y	Phase 1	[3]

References

• [1] National Cancer Institute Drug Dictionary (drug id 670651).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)